Publications
Publications
Show Results For
- All HBS Web
(47)
- Faculty Publications (15)
Page 1 of 15
Results
- September 2024
- Article
Standing on the Shoulders of Science
By: Joshua Lev Krieger, Monika Schnitzer and Martin Watzinger
Today’s innovations rely on scientific discoveries of the past, yet only some corporate
R&D builds directly on scientific output. In this paper, we analyze U.S. patents to
investigate how firms generate value by building on prior art “closer” to science. We
show... View Details
- 2024
- Working Paper
Old Moats for New Models: Openness, Control, and Competition in Generative AI
By: Pierre Azoulay, Joshua L. Krieger and Abhishek Nagaraj
Drawing insights from the field of innovation economics, we discuss the likely competitive environment shaping generative AI advances. Central to our analysis are the concepts of appropriability—whether firms in the industry are able to control the knowledge generated... View Details
- 2024
- Working Paper
Dusting Off the Old Ones: Drug Licensing to Startups, Innovation Success and Efficiency
By: Mosab Hammoudeh, Joshua Lev Krieger and Jiajie Xu
This paper investigates whether moving R&D from incumbents to startups can increase innovation. Using comprehensive drug development data, we examine the outcomes of drug projects licensed from large firms to startups. We find that these projects licensed to startups... View Details
- April 2024 (Revised August 2024)
- Case
The Engine
By: Joshua Lev Krieger, Jim Matheson, Fiona Murray and Nicholas Christman
The Engine, a venture capital firm founded by MIT to fill a gap in the technology funding landscape by commercializing breakthrough science and technology. Led by managing partner and CEO Katie Rae, the Engine's unique approach involved an unusually longer fund life,... View Details
- February 2024
- Supplement
Fusion Industry Association: Igniting the Future of Clean Energy
By: Kyle Myers and Joshua Lev Krieger
- January 2024
- Case
Fusion Industry Association: Igniting the Future of Clean Energy
Fusion energy is evolving from a scientific idea to a commercial possibility, drawing large investments and regulatory discussions; how should the FIA navigate this evolution?
The Fusion Industry Association (FIA) is at the forefront of transforming fusion... View Details
The Fusion Industry Association (FIA) is at the forefront of transforming fusion... View Details
- August 2022
- Teaching Note
In-Q-Tel: Innovation On A Mission
By: Josh Lerner and Joshua Lev Krieger
Teaching Note for HBS Case No. 823-031. View Details
- August 2022
- Case
In-Q-Tel: Innovation On A Mission
By: Joshua Lev Krieger and Josh Lerner
In 2022, the leaders of In-Q-Tel (IQT) considered what was next for the unique mission-driven organization. Since 1999, IQT had one mission: to be the most sophisticated source of strategic technical knowledge and capabilities to the U.S. government and its allies. IQT... View Details
- January 2022 (Revised March 2022)
- Teaching Note
Catalys Pacific
Teaching Note for HBS Case No. 821-035. View Details
- May 2021
- Article
Private and Social Returns to R&D: Drug Development and Demographics
By: Efraim Benmelech, Janice Eberly, Dimitris Papanikolaou and Joshua Krieger
Investment in intangible capital such as R&D has increased dramatically since the 1990s. However, productivity growth remains sluggish in recent years. One potential reason is that a significant share of the increase in intangible investment is geared toward consumer... View Details
- September 2020 (Revised January 2021)
- Case
Catalys Pacific
In 2019, BT Slingsby founds Catalys Pacific, the first biotech “venture creation” fund in Tokyo. After convincing some of the biggest Japanese pharmaceutical firms to invest, BT hopes the fund can make a big splash and transform biotechnology innovation in Japan. After... View Details
Keywords: Pharmaceutical Companies; Biotech; Health Care; Entrepreneur; Innovation; International Business; Entrepreneurial Finance; Entrepreneurship; Finance; Innovation Strategy; Venture Capital; Strategy; Cross-Cultural and Cross-Border Issues; Pharmaceutical Industry; Biotechnology Industry; Tokyo
- November 2017
- Case
The 'Wonder Drug' That Killed Babies
By: Joshua Lev Krieger, Tom Nicholas and Matthew Preble
In the early 1960s, a popular drug taken by patients worldwide for a range of maladies was found to cause severe birth defects and other health problems in babies born to mothers who had taken it during a certain stage of fetal development. As many as 10,000 children... View Details
Keywords: Regulation; Business and Government Relations; Business and Community Relations; Business and Stakeholder Relations; Product Marketing; Corporate Social Responsibility and Impact; Business History; Health; Government Legislation; Corporate Accountability; Ethics; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; Public Administration Industry; United States; United Kingdom; Australia; Germany; Europe
- Article
The Career Effects of Scandal: Evidence from Scientific Retractions
By: Pierre Azoulay, Alessandro Bonatti and Joshua Lev Krieger
We investigate how the scientific community's perception of a scientist's prior work changes when one of his articles is retracted. Relative to non-retracted control authors, faculty members who experience a retraction see the citation rate to their earlier,... View Details
- Research Summary
Overview
In examining the competitive dynamics of R&D strategy, Josh has become particularly interested in how the introduction of new knowledge generated by rivals impacts the direction of R&D efforts. Understanding how new information alters project portfolio decisions is... View Details